<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887717</url>
  </required_header>
  <id_info>
    <org_study_id>TS-104</org_study_id>
    <secondary_id>2012-005375-14</secondary_id>
    <nct_id>NCT01887717</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein</brief_title>
  <acronym>YES-P</acronym>
  <official_title>A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Italy: Agenzia Italiana del Farmaco (AIFA) &amp; Ministero della Salute</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled
      clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of
      care therapy (sorafenib) in the treatment of patients with inoperable liver cancer and
      blockage of the portal vein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this phase III, prospective randomized trial is to determine whether
      TheraSphere provides a meaningful benefit in survival in comparison with the standard of
      care (sorafenib) in patients with good hepatic function and advanced hepatocellular
      carcinoma (HCC) associated with portal vein thrombosis (PVT).

      This is an open-label prospective, multi-center, randomized, controlled clinical trial that
      will evaluate the use of TheraSphere compared to standard-of-care sorafenib alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>from time of randomization up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>primary endpoint is overall survival measured from time of randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>from randomization up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events classified according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) will be assessed on the basis of frequency and severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>from randomization up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological time to progression will be assessed using multiple methodologies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma With Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Standard of care treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in the Control group will receive SOC treatment with sorafenib in accordance with the package insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TheraSphere</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive treatment with yttrium-90 microspheres in accordance with the package insert.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TheraSphere</intervention_name>
    <arm_group_label>TheraSphere</arm_group_label>
    <other_name>yttrium-90 microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>standard of care therapy for treatment of advanced hepatocellular carcinoma</description>
    <arm_group_label>Standard of care treatment</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age, regardless of race of gender

          -  Advanced unresectable hepatocellular carcinoma with branch portal vein thrombosis
             (confirmed by non-invasive criteria EASL/AASLD, mandatory by histology in
             non-cirrhotic patients); can be naive or recurrent HCC after curative treatment (&gt; 6
             months before randomization)

          -  Unilobar disease

          -  Child Pugh A

          -  Tumor volume ≤ 70% of liver volume (determined by visual estimation)

          -  At least one uni-dimensional HCC target lesion assessable by CT or MRI according to
             RECIST 1.1

          -  ECOG Performance Status 0-1

          -  Platelets ≥ 50 X 10³/µL

          -  WBC ≥ 1.5 X10³/µL

          -  AST/ALT ≤ 5 X upper limit of normal

          -  Creatinine ≤ 2.0 mg/dL

          -  Life expectancy &gt; 3 months

          -  Signed informed consent

        Exclusion Criteria:

          -  Confirmed extra hepatic metastases. Patients with indeterminate hepatic hilar lymph
             nodes up to 2.5 cm in greatest dimension, or with indeterminate lung nodules (single
             lesion between 1-1.5 cm, or multiple smaller lesions with a total diameter ≤ 2 cm)
             may be included if metastatic disease is deemed unlikely

          -  Known contraindication to standard-of-care sorafenib including allergic reaction,
             pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease,
             significant GI bleed within 30 days, renal failure including dialysis

          -  Evidence of hepatic vein invasion or caval thrombosis

          -  Evidence of chronic obstructive pulmonary disease

          -  Indication for any possible curative treatment after multidisciplinary assessment
             (surgery, ablation, transplantation)

          -  Previous treatment with sorafenib for more than 4 weeks during the previous 2 months;
             prior sorafenib-related toxicity

          -  Initiation of anti-tumor therapy including chemotherapy or investigational drug
             treatment within 30 days before beginning study

          -  Prior TACE &lt; 6 months prior to screening phase in case of patients progressing from
             an intermediate to an advanced stage due to occurrence of PVT

          -  Patients cannot be on a transplant list

          -  History of organ allograft

          -  Contraindications to angiography or selective visceral catheterization

          -  History of severe allergy or intolerance to contrast agents, narcotics, sedatives or
             atropine that cannot be managed  medically

          -  Prior external beam radiation therapy to the liver

          -  Evidence of continuing adverse effect of prior therapy

          -  Active GI bleeding and any bleeding diathesis or coagulopathy that is not correctable
             by usual therapy or hemostatic agents

          -  Evidence of any disease or condition that would place the patient at undue risk and
             preclude safe use of TheraSphere treatment

          -  Females of child-bearing potential must have a negative serum test Participation in
             concurrent clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Mazzaferro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Tumori Nazionale, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riad Salem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University, Chicago, Illinois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation, Div of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlene del Castillo</last_name>
      <phone>312-695-1518</phone>
      <email>carlene.castillo@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Kulik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Nazionale Tumori di Milano</name>
      <address>
        <city>Milano</city>
        <zip>I-20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Brunero</last_name>
      <phone>+39 02 2390 3238</phone>
      <email>federica.brunero@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Simona Marchesi</last_name>
      <phone>+39 02 2390 3256</phone>
      <email>simona.marchesi@istitutotumori.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Prof Vincenzo Mazzaferro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona. IDIBAPS. CIBEREHD. Liver Unit</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Rengel</last_name>
      <phone>+34 9322 79235</phone>
      <email>IRENGEL@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Jordi Bruix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro, Gastroenterology &amp; Hepatology Dept</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maca Gomez</last_name>
      <phone>+1 34 607 944 154</phone>
      <email>mgadelhuph@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose L Calleja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Catala</last_name>
      <phone>+1 34 687565382</phone>
      <email>anacatgre@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Perez-Enguix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodie Hodgson</last_name>
      <phone>+1 44 121 697 8413</phone>
      <email>Jodie.Hodgson@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Yuk Ting Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hamilton</last_name>
      <phone>+44 0207 794 0500</phone>
      <phone_ext>35590</phone_ext>
      <email>sarahamilton@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>portal vein thrombosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
